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Abstract
Background: Africa in the twenty-first century is faced with a heavy burden of disease, combined with ill-equipped medical
systems and underdeveloped technological capacity. A major challenge for the international community is to bring scientific and
technological advances like genomics to bear on the health priorities of poorer countries. The New Partnership for Africa's
Development has identified science and technology as a key platform for Africa's renewal. Recognizing the timeliness of this
issue, the African Centre for Technology Studies and the University of Toronto Joint Centre for Bioethics co-organized a course
on Genomics and Public Health Policy in Nairobi, Kenya, the first of a series of similar courses to take place in the developing
world. This article presents the findings and recommendations that emerged from this process, recommendations which suggest
that a regional approach to developing sound science and technology policies is the key to harnessing genome-related
biotechnology to improve health and contribute to human development in Africa.
Methods: The objectives of the course were to familiarize participants with the current status and implications of genomics for
health in Africa; to provide frameworks for analyzing and debating the policy and ethical questions; and to begin developing a
network across different sectors by sharing perspectives and building relationships. To achieve these goals the course brought
together a diverse group of stakeholders from academic research centres, the media, non-governmental, voluntary and legal
organizations to stimulate multi-sectoral debate around issues of policy. Topics included scientific advances in genomics
innovation systems and business models, international regulatory frameworks, as well as ethical and legal issues.
Results: Seven main recommendations emerged: establish a network for sustained dialogue among participants; identify
champions among politicians; use the New Plan for African Development (NEPAD) as entry point onto political agenda;
commission an African capacity survey in genomics-related R&D to determine areas of strength; undertake a detailed study of
R&D models with demonstrated success in the developing world, i.e. China, India, Cuba, Brazil; establish seven regional research
centres of excellence; and, create sustainable financing mechanisms. A concrete outcome of this intensive five-day course was
the establishment of the African Genome Policy Forum, a multi-stakeholder forum to foster further discussion on policy.
Conclusion: With African leaders engaged in the New Partnership for Africa's Development, science and technology is well
poised to play a valuable role in Africa's renewal, by contributing to economic development and to improved health. Africa's first
course on Genomics and Public Health Policy aspired to contribute to the effort to bring this issue to the forefront of the policy
debate, focusing on genomics through the lens of public health. The process that has led to this course has served as a model
for three subsequent courses (in India, Venezuela and Oman), and the establishment of similar regional networks on genomics
and policy, which could form the basis for inter-regional dialogue in the future.
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Background
Inequities in global health continue to be among the
major challenges facing the international community [1].
Despite tremendous advances in medicine, the benefits of
science and technology have yet to make a major impact
on the health and quality of life of majority of the world's
population. Recognizing its fundamental role as engine
for development, the New Partnership for Africa's Devel-
opment (NEPAD) has identified science and technology
as a key platform for Africa's renewal [2]. A major chal-
lenge for Africa, and for the entire international commu-
nity, is to bring scientific and technological advances to
bear on the health priorities of poorer countries [3,4].
Africa in the twenty-first century is faced with a heavy bur-
den of disease, combined with ill-equipped medical sys-
tems and underdeveloped technological capacity [5]. The
crippling poverty in many countries in the continent con-
tributes to the disease burden, and hampers countries'
ability to address the problem adequately [6]. While
Africa's response to its health challenges has varied con-
siderably across the continent, with governments tradi-
tionally placing less emphasis on developing S&T than
other sectors [7], there has been ongoing R&D activity in
genomics and related fields of technology over the past
several years in various parts of the region. The African
Medical Research Foundation (AMREF), Africa's largest
indigenous health charity, has for nearly half a century
made an important contribution to addressing health
challenges in Africa through partnerships with local com-
munities, governments and donors [8]. A number of cen-
tres of excellence have emerged across the continent in
recent decades, including the International Centre of
Insect Physiology and Ecology (ICIPE) in Nairobi where
important work has been done to uncover the role of
insects in the transmission of infection http://
www.icipe.org, and the Institute for Molecular and Cell
Biology-Africa (IMCB-A), founded in 1999 to study the
molecular mechanisms of tropical infections. A further
example is the new Biosciences Facility for Eastern and
Central Africa that was recently launched as part of a
NEPAD initiative [9]. NEPAD, which has been adopted by
the United Nations General Assembly as Africa's develop-
ment framework, has called "for the establishment of
regional platforms with concrete actions to build and
strengthen Africa's competence to harness and use new
technologies for human development" [2]. Its strategy
acknowledges that Africa will have to overcome consider-
able challenges, including creating adequate regulatory
and biosafety frameworks, building scientific capacity,
and developing integrated systems of innovation.
In March 2002, the African Centre for Technology Studies
(ACTS) and the University of Toronto Joint Centre for
Bioethics (JCB) co-organized an intensive five-day Course
on Genomics and Public Health Policy in Nairobi, Kenya,
bringing together scientists, policy makers, journalists,
lawyers and NGOs from ten African countries to discuss,
collectively, the question of "How best to harness genom-
ics to improve health in Africa?" This course was spon-
sored by Genome Canada, the International
Development Research Centre, and the African Centre for
Technology Studies, through the Norwegian Agency for
Development Co-operation. The primary goal of the
course was to familiarize participants with the potential of
genomics and related biotechnologies to address health
needs in Africa. This article presents the findings and rec-
ommendations that emerged from this process, and sug-
gests how such courses might be more broadly employed
as a method for bringing together opinion leaders to share
ideas and work collectively to develop practical policy
solutions.
Methods
The programme was planned collaboratively by the Afri-
can Centre for Technology Studies and the Joint Centre for
Bioethics. The basic layout of the sessions and their topics
was modelled on a prior course held in Toronto, Canada
in May 2002. The programme was organized in line with
the objectives outlined in Table 1. Course participants as
well as session leaders were identified on the basis of rec-
ommendations from recognized experts in the region and
through literature searches. Many session leaders were
local experts, well placed to contextualize the "new sci-
ence" of genomics within the frame of concerns and real-
ities particular to Africa. Care was taken to select
participants representing a range of interests and back-
grounds, including individuals from science, economics,
law, government, the press, and non-governmental organ-
izations. Such diversity was sought in recognition of the
importance of "cross-pollination" on a multifaceted topic
like genomics, and consequently the need for multiple
actors to be part of the building of policy, as well as medi-
ating the dialogue between policymakers and the public.
In total, 30 participants attended; the countries and the
institutions they represent are listed in Table 2. Despite
concerted efforts to draw a balanced group, the partici-
pant list reveals a markedly high proportion of academics,
and indeed no representatives from industry. Moreover,
only three of the participants are women. The organizers
covered all costs for attending the course (transportation,
hotel accommodation, and meals), in order that inability
to pay not be an inhibiting factor for those who wished to
participate.
Because of the diversity of the participants, no back-
ground in science was presupposed. The sessions were
organized so that participants were first introduced to the
subject of the "new science" of genomics, and were then
instructed in areas including national innovation systems,Health Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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business models, intellectual property rights, interna-
tional conventions and regulatory structures, ethics, and
the role of networks in facilitating dialogue, advocacy and
policy making. A detailed time-table of the programme is
shown in Table 3. Presenters used overhead transparen-
cies or presentation software such as Microsoft Power-
point. Active participation was encouraged throughout
with at least 45 minutes allotted for discussion at the end
of each session, on the assumption that each participant
brought considerable expertise and valuable practical
experience of his or her own. The programme therefore
employed a peer-learning environment in which partici-
pants could learn from each other, in addition to learning
from material presented by instructors. Each participant
was provided with a course reader, which included addi-
tional background material on session topics; class ses-
sions used a variety of learning methods including
lectures, discussions, case analysis, and simulations.
Early in the course, participants were divided into small
Study Teams consisting of persons with diverse back-
grounds, in order to maximize complementary skills.
These Study Teams were an integral part of the learning
process of the programme. Sessions were intended
primarily to provide input for participant Study Teams,
which assembled several times during the week. Their pri-
mary task was to draw upon the course material and their
own experiences to propose recommendations for policy
relating to genomics and biotechnology in Africa. Presen-
tations were made on the last day of the course, and the
final sessions focused on how to take forward the ideas
and proposals generated during the course.
This was the first course of its kind in Africa, as well as the
first of a series of planned courses on genomics policy to
be held in developing countries; evaluation was therefore
a key component of the programme. At the end of each
day, participants were given a questionnaire to complete,
in which they had an opportunity to evaluate the day's
sessions. At the end of the course, participants were asked
to complete a more detailed questionnaire, asking for
their feedback on the overall aims and organization of the
course.
Results
The course opened with an Introduction, where Prof.
Abdallah Daar and Dr John Mugabe welcomed the partic-
ipants, explained the course's objectives, and then invited
each of the participants to introduce him- or herself to the
rest of the group. The opening session was led by Dr
Stephen Scherer, and was intended to provide a compre-
hensive overview of the science of genomics and its rele-
vance to health. Several of the participants had a limited
scientific background; the presentation therefore include
very basic descriptions of the science involved, as well as
images and a brief video, and gradually progressed to a
discussion of its applications in health research and med-
icine, both now and in the future. This session was fol-
lowed by an introduction by Prof. Onesmo ole-MoiYoi, a
pioneering Kenyan scientist, to advances in genomics and
molecular biology within the African context – including
cutting-edge research at his institute and others on the
continent, as well as the broader relevance of genomics
and molecular approaches to the health of Africa's people,
animals and the environment. The first day closed with a
Table 1: Objectives of the course
• To familiarize participants with the current status and implications of 
genomics and biotechnology for health in India, and to provide 
information relevant to public policy
• To provide frameworks for analyzing and debating the policy issues 
and related ethical questions, and to help understand, anticipate and 
possibly influence the legal and regulatory frameworks which will 
operate, both nationally and internationally
• To begin developing an opinion leaders network across different 
sectors (industry, academic, government, and voluntary organizations) 
by sharing perspectives and building relationships
Table 2: Countries and Institutions Represented
African Centre for Technology Studies, Kenya
African Malaria Vaccine Testing Network (AMVTN), Tanzania
African Medical and Research Foundation, Kenya
Centre for the Development of People (CEDEP), Uganda
Chemistry Department, University of Zambia, Zambia
Department of Biochemistry, University of Khartoum, Sudan
Department of Epidemiology of Parasitic Disease, National School of 
Medicine and Pharmacy, Mali
Department of Obstetrics and Gynecology, Assiut University, Egypt
Department of Pathology, Makarere University, Uganda
Department of Virology, University of Ibadan, Nigeria
Division of Human Genetics, Faculty of Health Sciences, University of 
Cape Town, South Africa
Dysmorphology and Alcohol Pharmacokinetics in Fetal Alcohol 
Syndrome, South Africa
Federal Ministry of Science and Technology, Nigeria
Inter-Region Economic Network (IREN), Kenya
Journalist Against AIDS (JAAIDS), Nigeria
Lawyer, Kenya
Maternal, Child and Women's Health, Dpt. of Health, Western Cape 
Province, South Africa
Molecular Biology Research Facility, Nelson R Mandela School of 
Medicine, South Africa
National Council for Science and Technology, Kenya
National Health Laboratory Service and Division of Human Genetics, 
University of Witwatersrand, South Africa
School of Public Health, University of Ghana, Ghana
Science and Development News, and BiotekAfrika, Kenya
Science Secretary, Uganda Council for Science and Technology, 
Uganda
The People Newspaper, KenyaHealth Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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session led by Dr Peter Singer who described a five-point
strategy to systematically capture the benefits of genomics
for the health of citizens in developing countries, through
research, capacity-strengthening, consensus-building,
public engagement, and an investment fund. Examples of
ongoing work by the University of Toronto's Canadian
Program on Genomics and Global Health in these areas
were discussed, including the results of its 2002 study to
identify the most promising biotechnologies to improve
health in developing countries [13].
Prof. Joseph D'Cruz opened the second day with a discus-
sion introducing participants to new approaches to form-
ing and expressing opinions about emerging issues using
the internet. Leaders in any area are required to develop
their own views about new developments in their fields,
and the process of forming these views is facilitated by
peer discussions. Though traditionally these processes
have taken place face-to-face, the internet offers an alter-
native medium that allows individuals to interact with
their peers in other locations at a time and pace suited to
each individual's commitments, without forcing the
group to reach early consensus. Prof. Norman Clark fol-
lowed with a session aimed at introducing participants to
the concept of 'National Systems of Innovation', a
conceptual framework for analysing country-specific fac-
tors that influence innovation across sectors. Innovation
is understood as processes of generating new ideas, prod-
ucts and production processes, as well as to processes of
institutional change and development. Such frameworks
can be useful in identifying and analyzing key factors
affecting African countries' ability to engage effectively in
biotechnology and genomics for human development.
The last session of the day focused on the business life
cycle of a genomic product, tracing its development from
the laboratory bench to a patented invention that is
exploited commercially. The session addressed the strate-
gic issues and choices that firms face at each point in this
life cycle, and used a case-study based approach to frame
the issues. The last one-and-a-half-hour session of the day
was devoted to group work among members of Study
Teams, whose members were selected to bring diverse
views and experiences to bear on their deliberations.
The third day of the course was devoted primarily to the
issue of intellectual property rights (IPRs). The two ses-
sions on IPRs were led by Dr Patricia Kameri-Mbote, Ken-
yan lawyer and scholar. During the first of these, Dr
Kameri-Mbote explained the nature and different kinds of
IPR protection, and explored how these impact on bio-
technology development and technology transfer. She
also considered the relationship between IP protection
and public health in developing countries, using specific
cases that have arisen under the World Trade Organiza-
tion's Agreement on Trade Related Aspects of Intellectual
Property Rights (TRIPS). Positions held by different coun-
tries and scholars on IP and biotechnology transfer in
health were examined, and international, regional and
national intellectual property regimes were reviewed. The
second session focused on the link between IP, public
health and transfer of biotechnology, in addition to the
ethical, social and policy implications of the "Doha Dec-
laration" on health by WTO ministers intellectual prop-
erty rights in the area of health under TRIPS. At the end of
Table 3: Agenda for the Course on Genomics and Public Health Policy in Africa.
T i m e D a y  1D a y  2D a y  3D a y  4D a y  5
9.00–10.30 Introduction
Prof Abdallah Daar, Dr 
John Mugabe
New Science I : 
Introduction
Dr Stephen Scherer
Internet-based Leader
Networking: Exercise
Prof Joseph D'Cruz
Intellectual Property 
Rights I
Dr Patricia Kameri-Mbote
Ethics I
Dr Peter Singer
Group Presentations
11.00–12.30 New Science II
Dr Stephen Scherer
National Innovation 
Systems
Prof Norman Clark
Intellectual Property 
Rights II
Dr Patricia Kameri-Mbote
Ethics II
Prof Abdallah Daar
Group Presentations 
Continued
1.30–3.00 New Science III
Prof Onesmo ole-MoiYoi
Business Models
Prof Joseph D'Cruz
Internet-based Leader 
Networking: Results
Prof Joseph D'Cruz
Science & Innovation 
Policy in International 
Conventions
Dr John Mugabe
3.30–5.00 Genomics and Global 
Health
Dr Peter Singer
Group Work Group Work Group WorkHealth Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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the third and fourth days, participants again met for 1.5
hours in their Study Teams to prepare their proposals.
Day four of the course had a heavy focus on ethical
dimensions of emerging technologies like genomics. The
first session provided an overview of ethical issues related
to genomics and public health policy. Prof. Abdallah Daar
led this and the second session on ethics. He described the
World Health Organization's draft Guiding Principles on
Medical Genetics and Biotechnology document, which he
co-authored and which provides a broad overview of the
ethical principles in this field. During the second session,
Prof. Daar and Dr. Singer led the group through a case
involving benefit sharing, and introduced the Human
Genome Organization's principles and statement on ben-
efit sharing. Dr. Singer then described an ethical frame-
work and approach to priority-setting for genomics
technologies in health care institutions. The last hour of
this session was devoted to providing a forum for partici-
pants to share their expertise and experiences in areas
related to policy. The final session of the day was led by Dr
John Mugabe, then-Director of the African Centre for
Technology Studies in Nairobi, Kenya. This session intro-
duced participants to international conventions and pro-
tocols that emerged out of the United Nations Conference
on Environment and Development (UNCED), and
focused on science and innovation issues covered by the
Conventions on Biological Diversity and its Cartagena
Protocol on Biosafety, and the International Treaty on
Plant Genetic Resources for Food and Agriculture. Specific
lessons were drawn for international rule-making for
health equity, and emphasis was given to biotechnology,
risks assessment, technology transfer, sharing benefits of
global scientific and technological advances, and techni-
cal cooperation.
On the last day, each of the four Study Teams presented
their proposals, which addressed the overarching ques-
tion of the course: "How to harness genomics and related
biotechnology to improve health in Africa?" Study Teams
presented one at a time; after each presentation, there was
a period for questions and discussion, and afterward an
opportunity to consider all proposals together in light of
the host of issues raised during the course of the week. The
presentations, though prepared independently by each
group, demonstrated a number of common themes that
tended to be organized in terms of long-term founda-
tional issues of sustainability, and more concrete short-
term issues relating to garnering political involvement.
Table 5 enumerates the key recommendations that
emerged from these sessions.
Discussion
The following is a synthesis of the participants' efforts,
summarizing and describing key issues that emerged from
their presentations and throughout the weeks'
deliberations. It includes several concrete action-steps
recommended by the participants, which flow from these
considerations.
Creating a Platform for Ongoing Dialogue and Advocacy
The course generated a great deal of enthusiasm and vig-
orous discussion, and there was consensus among the par-
ticipants on the need to create a mechanism for
capitalizing on this momentum. Course participants and
faculty therefore established an e-mail-based network, the
African Genome Policy Forum (AGPF), to allow the contin-
ued exchange of ideas and the building of consensus on
issues related to genomics and public health policy. The
group, composed of participants from areas of govern-
ment, academia, civil society and the media, was created
to bring to the table the views of their respective constitu-
encies, and inform their peers of insights gained from the
course and through the network. The network may also
play an advocacy role in promoting the responsible use of
genomics as a tool to improve health and promote devel-
opment in Africa.
Concrete Action-Step 1: Establish a regional network to foster 
sustained inter-sectoral dialogue
On the final day of the course, it was decided that a
regional network, the "African Genome Policy Forum", be
established comprising all participants and session lead-
ers; it was further agreed that the Joint Centre for Bioethics
would set up a web-site, discussion board, and e-mail
based platform to facilitate ongoing discussion and inter-
sectoral debate on the issues and proposals raised during
the course.
Mobilizing Political Support
The success of any major initiative requires sustained dia-
logue with politicians. It is important to take the time to
address their legitimate concerns, by clarifying the specific
relevance of genomics and its applicability within the con-
text of their communities. A point of particular relevance
is the link between technologies like genomics and
Table 5: Recommended Action-Steps
Establish a regional network to foster sustained inter-sectoral 
dialogue
Identify champions among politicians
Use the New Plan for African Development (NEPAD) as entry point 
onto political agenda
Commission African capacity survey in genomics-related R&D to 
determine areas of strength
Undertake a detailed study of R&D models with demonstrated 
success in the developing world
Establish seven regional research centres of excellence
Create sustainable financing mechanismsHealth Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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Africa's development, which has been well described in a
number of recent reports [e.g. [6,10]]. Participants high-
lighted the importance of taking back to their colleagues
in their respective countries and institutions the lessons
drawn from the course; those participants in public office
agreed to seize opportunities to raise some of issues and
proposals of the course when attending relevant forums.
In particular, the nascent New Partnership for Africa's
Development, adopted in 2001 under the mandate of the
Organisation of African Unity, was repeatedly pointed to
as an opportunity to bring genomics and its relevance to
health in Africa onto the political agenda. Science and
technology is among NEPAD's seven priority areas;
another is human development, which encompasses
health [11]. Genomics provides a clear example of how
these two areas – science and technology, and health –
come together, and can serve as a model for considering
how science and technology and health concerns can be
better integrated to address the continent's economic and
health needs.
Concrete Action-Step 2: Identify champions among politicians
The most efficient means of garnering political support is
often to go directly to the politicians themselves – those
who have been supportive or outspoken of the issues in
question – to put the subject before their colleagues. The
course itself represented an important step in this direc-
tion, as it brought together a spectrum of stakeholders,
including academics, civil society, and government offi-
cials. The course, and the subsequently established net-
work, therefore furnished an opportunity for direct
communication and dialogue among individuals with a
shared vision, including policymakers in a position to
"champion" the issues and proposals that emerged from
the course to their colleagues and others.
Concrete Action-Step 3: Use the New Plan for African 
Development (NEPAD) as entry point onto political agenda
NEPAD offers a possible forum to bring the subject of
genomics-related biotechnology onto the political
agenda, and provides a means of informing African lead-
ers of genomics and its relevance to improving health and
development in Africa. In particular, the AGPF recom-
mends the establishment by NEPAD of an 'African
Genomics Committee', which would provide a plan for
utilizing genomics and other new technologies to
enhance health in Africa, advocate for increased invest-
ment in S & T, target other relevant stakeholders in indi-
vidual countries, educate policy makers about the need
for a strong R&D base established through partnerships
across Africa, and organize steering committees to identify
gaps and implement strategies for improvement.
Prioritizing Needs
Participants agreed on the need to consider emerging
technologies like genomics in light of Africa's specific
health challenges, and consequently on the importance of
prioritizing these and identifying strategic entry points.
Infectious (including sexually transmitted) diseases,
genetic and other non-communicable disorders, sanita-
tion, nutrition, environmental pollution and loss of bio-
diversity were all proposed as areas requiring concerted
attention, with a special emphasis on the potential for
using genomics-related biotechnology to target the three
biggest killers in Africa: malaria, HIV/AIDS and tuberculo-
sis. There are already well-known African-led initiatives to
apply scientific innovation to combat important health
concerns, such as the Multilateral Initiative on Malaria,
and the African Malaria Vaccine Testing Network
(AMVTN). It will be important to build on existing success
stories, and to identify gaps in terms of priority health
areas receiving inadequate attention. This will help to
focus efforts and to more efficiently channel limited
resource, both financial and human. A regional approach,
which has since been adopted by NEPAD, was proposed
as a promising mechanism for harnessing existing compe-
tence to address local needs.
Concrete Action-Step 4: Commission African capacity survey in 
genomics-related R&D to determine areas of strength
This survey would identify strategic areas of strength, such
as existing centres of excellence, potential areas of
improvement, and health priorities receive inadequate
attention. It would also serve to identify local and
national innovators, and to inform the structuring of
Regional Centres of Excellence described below.
Capacity Building & Public Engagement
For several years, genomics has been linked with a
number of high-profile, intensely controversial issues like
human cloning and genetically modified organisms.
While emerging technologies like genomics raise a
number of important ethical and social issues that deserve
careful consideration [12], a nuanced message takes
account of the possibilities as well as the challenges of
new approaches. Often, technological applications can
complement existing, well-established health approaches
[13]. Scientists, policy-makers, and the media have an
important part to play in publicizing science, and point-
ing out its relevance to Africans in a moderate rather than
hyperbolic tone [14]. Local leaders can have an important
role to play, not only in reflecting the leading-edge opin-
ions of their different constituencies to policymakers, but
also by playing a role in raising awareness within their
communities. A more informed public is often a more
engaged public, which can effectively advocate for the
development of policies that reflect legitimate concerns,Health Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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while leaving space to explore promising avenues of scien-
tific endeavour.
Public engagement was seen to form part of a long-term
strategy for capacity building, and raising the overall pro-
file of science and technology in Africa. The discussions
reflected a conception of capacity strengthening as inti-
mately linked with quality education – at all levels, and
across disciplines. Core to this debate among course par-
ticipants was the belief that endogenous capacity must be
developed in order that Africa can begin to be self-suffi-
cient, and itself become an innovator. Participants identi-
fied the following categories as needing attention:
Primary, secondary and tertiary education
There is a need to introduce innovative techniques to
teach science and technology in the classroom, in order to
generate interest and aptitude in the subject matter from
an early stage in the educational process. Besides contem-
porary scientific approaches, indigenous knowledge and
its applications to health could also be a relevant compo-
nent to include in the curriculum.
Policymakers
Those in a position to shape policy should be familiarized
with codes of ethics pertaining to their field; moreover,
they should be educated about how best to capitalize on
international frameworks (e.g. WTO's Trade-Related
Aspects of Intellectual Property Rights; the UN's Conven-
tion on Biological Diversity) in order to ensure that their
countries benefit from such arrangements, and are not
exploited. Policy makers should develop strategies for
negotiating their interests collectively in international
forums, when appropriate, given shared needs and values.
Media
There is a general need to strengthen capacity in the area
of communication, in particular on increasing the level of
science literacy among the media. This might include inte-
grating journalism and science programs at the college
and university levels. There is a corresponding need to
improve the ability of scientists to communicate the rele-
vance of their work to the public, and to policy-makers.
ELSI
There is a great need to build capacity in Africa with regard
to the ethical, legal and social issues (ELSI) which inevita-
bly accompany the emergence of new technologies. Strat-
egies would in many cases involve sensitizing the public
to issues of relevance, such as their rights as patients and
participants in research (e.g. informed consent, confiden-
tiality of patient information), encouraging dialogue
about the social consequences of introducing new tech-
nologies into traditional settings, and putting frameworks
in place (e.g. ethics review boards) to ensure that ethical,
quality and safety standards before research is undertaken.
Partnerships
Along with the need to strengthen the R&D base in science
and technology, participants of the course identified a
related need to increase the emphasis on commercializa-
tion – not only as a tool for sparking innovation but also
to permit the generation of capital necessary to sustain the
industry. An important step in the process of moving
toward commercialization is the forming of alliances
within countries, between universities and industry,
sometimes known as "cross-linking". The fruitfulness of
the Africa course, where people from across sectors and
sub-regions came together with a common mission, re-
enforced the value and the importance of establishing
cross-sectoral networks and collaborations. Networks pro-
vide a means of generating new ideas, pooling the creative
energies of individuals, and exchanging advice and
expertise around a particular area of focus, in this case
genomics and health policy. Such networks could play an
advocacy role, combining the voices and the influence of
key players from diverse disciplines and sectors, to
advance a common aim. Collaborations, at the level of
institutions – both within and between countries and
regions – would facilitate the transfer of both knowledge
and technology. During the course, it was pointed out that
there is a particular need to encourage linkages between
universities and industry to, among other things, facilitate
the move from research and development to product gen-
eration and commercialization. This could include mech-
anisms to facilitate relationships between universities
undertaking research in biotechnology and local indus-
tries. Institutional partnerships and collaborations at all
levels, including internationally, can mean the channel-
ling of resources to common areas of focus, and pooling
the relative strengths and resources of partner institutions
[15]. Such collaborations require very clearly defined roles
for partners, and transparency with respect to goals, prior-
itization of needs, funding, and mechanisms to ensure
equitable access to products.
Creating sustainable financing mechanisms
Ensuring that the benefits of science and technology,
including emerging fields like genomics, requires a long-
term strategy for sustained investment.
Concrete Action-Step 5: Design proposals for obtaining sustained 
investment for both research and development (R&D) in genomics 
and related biotechnologies to improve health, and the 
commercialization of the products of R&D
Three models were suggested
The establishment of an African Science and Technology Fund,
dedicated to supporting research and development in theHealth Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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area of health-related biotechnology, would rely upon the
contribution of African governments.
The establishment of an Investment Fund for genome-related
biotechnologies for improving health would represent an
innovative approach to obtaining capital, providing a fur-
ther incentive for investors to put money into develop-
ment by creating a fund that provides a return on
investment, as well as furnishing funds for advancement.
Such a fund might be dedicated to providing capital for
the development of mature, or future, health-related
technologies.
Capitalizing on existing funds allocated for research related
to diseases afflicting Africa, such as the WHO's Global
Fund to Fight   AIDS, Tuberculosis and Malaria. Genomics
and biotechnology represents a powerful set of tools for
health improvement, and the World Health Organization
through its Genomics and World Health (2002) report has
raised it as an important issue deserving international
attention. It is important to use this positive emphasis to
give weight to the case for the relevance of biotechnology
to health in developing countries, particularly for policy
makers.
Research and Development (R&D)
With respect to R&D, there are already areas of strength on
the continent; it is crucial to identify localized expertise,
and to establish linkages with centres elsewhere in the
region, as well as abroad, to ensure the transfer of knowl-
edge and of technology, and to facilitate human resource
development. Infrastructure must be developed to attract
qualified African researchers to remain in or to return to
Africa – both to support them, technically, intellectually,
and socially and to provide them with similar opportuni-
ties for creativity and growth as may be found in other
locales. The Biosciences Facility, established in 2003 by
NEPAD, takes up this challenge, promoting "scientific
excellence by bringing together a critical mass of scientists
drawn from national, regional and international institu-
tions in state-of-the-art facilities where they can undertake
cutting-edge research to help solve the most important
development constraints faced by the poor in Africa" [9].
While the new Biosciences Facility is the first of network
of centres of excellent focused primarily on using science
to help poor farmers, it may be an appropriate model for
like initiatives using a regional approach for targeting
health challenges.
Concrete Action-Step 6: Undertake a detailed study of R&D 
models with demonstrated success in the developing world, i.e. China, 
India, Cuba, Brazil
Developing countries in various parts of the world have
proven that they too can have strong technology sectors,
and make important contributions in terms of science and
innovation. Their successes represent an opportunity to
bring to the attention of politicians that there are coun-
tries succeeding in genomics. A detailed study of these
models can provide important insights into how Africa
can capitalize on the promise of genomics and biotech-
nology, particularly as it relates to health. In 2003, the
Joint Centre for Bioethics completed a qualitative study of
R&D in biotechnology in South Africa; similar studies are
underway in Cuba, Egypt and China. Research of this kind
could feed into more systematic efforts in the region to
better understand how some developing countries,
including those in Africa, have managed to develop S&T
research and manufacturing capacity in the health sector.
Concrete Action-Step 7: Establish Seven Regional Research 
Centres of Excellence
The proposed centres would be distributed across North-
ern, Southern, Eastern, Western and Central African sub-
regions. Each centre would have its own area of focus, in
terms of targeted health problems, depending on regional
expertise. The Centres would not be the sole preserve of
each region, but would in fact use the strengths and spe-
cializations of each region to achieve the goal of harness-
ing genomics to improve health in Africa. These regional
centres of excellence need not preclude the existence of
national centres of excellence. The Biosciences Facility is
modelled on such an approach.
Conclusion
Analysis
The course on Genomics and Public Health Policy in
Africa was carefully designed, with inputs from both its
Canadian and African co-organizers, to have a programme
and participant profile reflecting the inter-disciplinarity of
the issue being considered. Genomics cuts across S&T,
environmental, development, industrial, education and
health policy and generates important ethical, legal and
social issues. It therefore requires a genuinely participa-
tory and multi-stakeholder approach, as well as frank dis-
cussions about both the potential promise and perils of a
relatively new science.
The strength of the course, as reflected in the evaluations
submitted by participants, was the rare opportunity for
discussion and networking among opinion leaders from
different sectors. Both during and between sessions, par-
ticipants exchanged perspectives and experiences with
others from different regions of the content, and from dif-
ferent disciplines. Senior political officials, journalists,
academics, and civil society representatives worked
together in Study Teams to create proposals. Discussions
were lively and open, with broad participation from those
in attendance. However, a weakness of the course was the
absence of industry representatives, who would certainly
have contributed an important and valuable point ofHealth Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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view. The small number of women participants was also a
notable disadvantage. Later courses modelled on the Nai-
robi offering (i.e. those in Latin America, the Eastern Med-
iterranean, and India) had greater success in drawing
participants from industry and obtaining a better gender
balance. Notably, however, the recommendations that
emerged from these courses, while reflecting differences
due to regional priorities and context, did not vary consid-
erably despite the broader contribution, particularly from
the private sector [20].
A major outcome of the Nairobi course, and one which
had strong support from participants, was the creation of
a virtual network to facilitate ongoing interaction and dis-
cussion. Within two weeks of its completion, a website
was created for the course http://www.utoronto.ca/jcb/
genomics/html/ACTS_main.htm, as well as a web-based
discussion board. While there was some initial activity on
the discussion board, this eventually subsided, and was
soon evident that this approach had failed. In an effort to
revive the momentum and to solicit ideas from AGPF
members about how to best move forward with the net-
work, a short survey was sent to members asking what
their needs were, both in terms of the network as well as
in terms of the technical facilities at their disposal. The
response rate was extremely low; however, those who pro-
vided feedback confirmed what the participation level
suggested: namely, that information technology facilities
in Africa are such that very few individuals, outside of
some well-equipped academic or private institutions,
have regular access to the internet. The web-based discus-
sion board was, therefore, in practice a highly unsustaina-
ble option for the majority of participants. The point was
also raised that it was not enough to be connected elec-
tronically; there was also a need to share a more tangible
goal or project, and to have a more visible leader from
within the group, to galvanize efforts and motivate con-
tinued interaction. One respondent explained that find-
ing the time to contribute to such networks is
extraordinarily difficult for many Africans, who often
"wear many hats". As a result, a general interest was insuf-
ficient to justify diverting time from other tasks; a con-
crete, realizable goal was essential for engaging
individuals who already feel over-stretched. As a conse-
quence of these inputs, an email-based forum was estab-
lished, since most AGPF members have better access to
email than to the internet, and a moderator was temporar-
ily appointed over the group. Activity on the forum
improved and continues today, more than two years later,
though interventions are irregular and generally extend to
the sharing of information or material of interest, rather
than discussions about issues.
The India course on Genomics and Public Health Policy
was held in January 2003, less than one year after the
inaugural Nairobi effort. Based on feedback from the pre-
vious course, the questionnaire requesting feedback about
participants' technical and substantive needs in relation to
the creation of a network was distributed during the
course, to permit the creation of a network that was much
more responsive to the needs of the participants. Modera-
tors from among the participants were nominated before
the course' end and their roles clarified, to facilitate the
sustainability and autonomy of the network.
Later in 2003, two further courses were held in Oman and
in Venezuela, both of which added a further element dem-
onstrating the learning from the first two courses. On
both occasions, the Joint Centre for Bioethics collaborated
with the Regional Offices of the World Health Organiza-
tion; in the first instance, with the Eastern Mediterranean
office (EMRO) and in the second, with the Pan-American
Health Organization (PAHO). This collaboration ensured
that the recommendations of each course had an
institutional structure through which they could be chan-
nelled, to reach the ear of decision-makers. EMRO and
PAHO have extensive links with ministries of health
within their regions, as well as with representatives from
civil society and industry. This provided an opportunity
for the results of the course to have a much wider impact.
By contract, the impact of the Nairobi course is very much
linked to the efforts of individual participants to engage
with their constituencies and with the NEPAD initiative,
of which one of their members is now a senior actor. The
Forum developed following the Nairobi course has not
provided a framework to drive action the way it was ini-
tially intended; however, it continues to provide a portal
for information-sharing and dialogue.
Final Remarks
The executive course on Genomics and Public Health Pol-
icy in Africa was the first of its kind to be held on the con-
tinent. The response of participants indicated a
tremendous enthusiasm for and interest in discussing the
emerging technology of genomics and its applications for
addressing the health woes of Africans. The sessions cov-
ered a spectrum of topics, from basic science, to ethics,
business models and international frameworks – exempli-
fying the range of intersecting issues relevant to informed
discussions about genomics and related policy. The course
also was a demonstration of the fruitfulness of a multi-
stakeholder approach. An important aim of the course
was to encourage network-building and the development
of meaningful interactions, as a foundation for sustained
dialogue among opinion leaders. Participants were
encouraged to develop independent proposals in a collab-
orative environment, rather than to be passive recipients
of "expertise" from the session leaders. The result was a
series of concrete proposals for action, and the establish-
ment of an e-network to provide a forum for ongoingHealth Research Policy and Systems 2005, 3:2 http://www.health-policy-systems.com/content/3/1/2
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communication, discussion and elaboration of the issues
and proposals raised during the course. Several partici-
pants agreed to raise the proposals and themes articulated
to their colleagues; the course also generated some public-
ity, as journalists invited to attend and to participate
actively in the meeting reported on the key issues in vari-
ous media [[16,17]; see also [18]].
Since the completion of this course, three more offerings
have taken place, one in India in collaboration with the
Indian Council for Medical Research (ICMR) in January
2003, another in Oman in August 2003, and a third in
Venezuela in 2004. A fourth course is being planned for a
venue in South-east Asia. The Nairobi offering demon-
strated clearly the receptiveness of African researchers and
policy makers to such an initiative, and captured the
vision of a cross-section of stakeholders around how to
ensure that the new wave of scientific promise does not
pass them by, or crush them in its wake, but instead is har-
nessed for better health and to further economic develop-
ment in their region [19]. The courses in India and Oman
similarly gave rise to regional e-networks [20], which may
eventually be connected to form an inter-regional forum
for dialogue to form a basis for the sharing of experiences
and expertise across regions in the developing world. Each
of the three executive course held to-date has addressed
similar themes in relation to genomics and health; but
each has also been adapted to the particular context and
interests of the host country or region. This has partly
been achieved through active collaboration between the
Joint Centre for Bioethics and the host institutions. The
electronic networks provide a means of generating a long-
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5 Science, Human Genome Volume, Vol. 291 Feb. 2001.
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term impact, driven by participants who are empowered,
in their particular capacities, to take forward the ideas
shared and the proposals developed through their interac-
tion. The Nairobi course also highlighted the importance
of being proactive in soliciting suggestions from partici-
pants about creative means of virtual networking that real-
istically address the poor information technology
infrastructure in most parts of Africa. It also was instruc-
tive in demonstrating that a network is not itself self-sus-
taining; it must be driven by a clear, shared vision among
participants, and possibly even a concrete and realizable
project. Moreover, ideally a moderator from within the
group should take leadership in feeding the forum, and
motivating ongoing participation.
The New Partnership for Africa's Development (NEPAD)
has made science and technology (including genomics
and biotechnology) a key platform in its plan for eco-
nomic renewal [2,9]. Indeed, the recommendations out-
lined above overlap considerably with those described in
a recent document detailing the resolutions of the first sci-
ence and technology workshop of NEPAD, held in Febru-
ary 2003 [2]. The recent establishment of the African
Biosciences Facility as a centre of scientific and technolog-
ical excellence in the region, is further evidence that the
recommendations articulated by the AGPF reflect a more
widely shared vision. There is a growing recognition in
Africa, and internationally, of the role that genomics and
biotechnology can play, not only in alleviating health
scourges of the poor, but also in addressing some of their
economic concerns. With appropriate emphasis on its
health needs, incentives for meaningful partnerships,
sound regulatory structures, innovation and foresight,
Africa could be in a position to benefit from genomics and
related fields of biotechnology. The Course and Genomics
and Health Policy in Africa had as its overarching goal that
of bringing together a vibrant cross-section of individuals
to foster dialogue around this timely issue. The African
Genome Policy Forum works to build on this foundation,
to sustain the momentum of the course, and to fulfill
some of the participants' proposed goals. Perhaps most
significantly, this series of courses represents a practical
and effective mechanism for drawing together a variety of
actors to address an issue of recognized import, which
deserves a truly inter-disciplinary approach. Moreover, it
is an initiative that generates important debate, but which
is ultimately focused around generating concrete proposals
to inform policymaking.
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